Evidence map›Paper›PMID 42741505›Full record

ArticleAnnals of surgical treatment and research2026

Clinical benefit of adjuvant chemotherapy in resected T2N0 distal cholangiocarcinoma: a retrospective cohort study.

Yoon Soo Chae, Youngmin Han, Seulah Park, Go-Won Choi, Younsoo Seo, Inhyuck Lee, Hye-Sol Jung, Young Jae Cho, Wooil Kwon, Jin-Young Jang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of surgical treatment and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yoon Soo ChaeDepartment of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0003-2762-3286
Youngmin HanDepartment of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0003-0456-7824
Seulah ParkDepartment of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0009-0009-2308-2153
Go-Won ChoiDepartment of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0009-0001-7815-9834
Younsoo SeoDepartment of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0009-0009-2096-6121
Inhyuck LeeDepartment of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0001-9261-7777
Hye-Sol JungDepartment of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-2041-4214
Young Jae ChoDepartment of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0003-2255-8390
Wooil KwonDepartment of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-4827-7805
Jin-Young JangDepartment of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0003-3312-0503
Joon Seong ParkDepartment of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0001-8048-9990

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Several studies have reported that adjuvant chemotherapy (AC) improves survival outcomes in patients with distal cholangiocarcinoma (dCCA). However, definitive evidence supporting the efficacy of AC in dCCA patients with early T-stage and node-negative disease remains lacking. This study aimed to investigate the clinical benefit of AC and prognostic factors in patients with the early stage of dCCA, with a focus on resected T2N0 dCCA. Methods: A total of 123 patients who underwent curative surgery with pathological confirmation of T2N0 dCCA between 2000 and 2022 were reviewed using prospectively collected clinicopathologic data. Results: No significant between-group differences were observed in 5-year overall survival (OS) (64.8% Conclusion: Routine use of AC did not significantly improve postoperative survival outcomes in patients with completely resected T2N0 dCCA, nor was its clinical benefit remarkably even in the high-risk group (positive resection margins). Therefore, achieving an R0 resection appears to be more important for improving postoperative survival outcomes in T2N0 dCCA.

Indexed as

Adjuvant therapyChemotherapyCholangiocarcinomaRadiotherapySurvival rate

Identifiers

PMID42741505
PMCPMC13574522

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.